MONROVIA, Calif., June 12, 2015 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that the Company will host a R&D Day on Friday, June 26, 2015, from 8:30 a.m. – 11:30 a.m. ET in New York City. During the R&D day, members of Xencor's management...
↧
